Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

MLA

Vassiliki A. Papadimitrakopoulou, et al. Data from Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6528081.v1.

APA

Vassiliki A. Papadimitrakopoulou, Richard B. Lanman, Justin I. Odegaard, Daniel Dix, Miguel A. Villalona-Calero, Karen L. Reckamp, Stephen G. Divers, Davey B. Daniel, Victoria M. Raymond, Ray D. Page, & Natasha B. Leighl. (2023). Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer. https://doi.org/10.1158/1078-0432.c.6528081.v1

Chicago

Vassiliki A. Papadimitrakopoulou, Richard B. Lanman, Justin I. Odegaard, Daniel Dix, Miguel A. Villalona-Calero, Karen L. Reckamp, Stephen G. Divers, et al. 2023. “Data from Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer,” March. doi:10.1158/1078-0432.c.6528081.v1.